Hosotani H, Ohashi Y, Yamada M, Tsubota K
Department of Ophthalmology, Osaka University Medical School, Japan.
Am J Ophthalmol. 1995 Mar;119(3):288-94. doi: 10.1016/s0002-9394(14)71169-9.
A randomized clinical study was undertaken to determine whether a topically applied aldose reductase inhibitor, CT-112, was capable of reversing the abnormal morphologic characteristics of corneal epithelial cells, as well as the reduced corneal sensitivity, in diabetic patients.
Thirty-nine diabetic patients were randomly divided into two groups: one group was treated with topical aldose reductase inhibitor (CT-112) in an ophthalmic preparation, and a control group was treated with the same preparation without the inhibitor. Specular microscopy was performed to analyze the morphologic characteristics of corneal epithelial cells before and after the treatment. Corneal sensitivity was measured by means of the Cochet-Bonnet esthesiometer.
The anterior surface area of superficial cells in the group treated with CT-112 was significantly decreased from a mean value of 881 to 728 microns2 (P < .0001), whereas the control group showed no significant changes. Corneal sensitivity remained decreased in the control group, whereas that in the group treated with CT-112 significantly improved, from 5.36 to 1.37 g/mm2 (P < .0001).
These results indicate that treatment with topical CT-112 is capable of reversing abnormal morphologic characteristics of corneal epithelial cells and reduced corneal sensitivity in diabetic patients.
开展一项随机临床研究，以确定局部应用醛糖还原酶抑制剂CT - 112是否能够逆转糖尿病患者角膜上皮细胞的异常形态特征以及降低的角膜敏感性。
39例糖尿病患者被随机分为两组：一组用眼科制剂中的局部醛糖还原酶抑制剂（CT - 112）治疗，对照组用不含该抑制剂的相同制剂治疗。治疗前后进行镜面显微镜检查以分析角膜上皮细胞的形态特征。通过Cochet - Bonnet触觉计测量角膜敏感性。
用CT - 112治疗的组中，表层细胞的前表面面积从平均值881显著降至728平方微米（P <.0001），而对照组无显著变化。对照组的角膜敏感性仍然降低，而用CT - 112治疗的组中角膜敏感性显著改善，从5.36降至1.37克/平方毫米（P <.0001）。
这些结果表明，局部应用CT - 112治疗能够逆转糖尿病患者角膜上皮细胞的异常形态特征和降低的角膜敏感性。
